AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31618863 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g of pure whey protein isolate (H)
Number of subjects: 18
Study 31618863 — intervention group
Group type: COMPARATOR
Intervention: 0 g of protein (C)
Number of subjects: 18
Study 27829249 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoy receptor 3 (DcR3)
Number of subjects: 23
Study 27829249 — intervention group
Group type: EXPERIMENTAL
Intervention: Trefoil factor 3 (TFF3)
Number of subjects: 23
Study 27829249 — intervention group
Group type: EXPERIMENTAL
Intervention: Midkine
Number of subjects: 23
Study 27829249 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 26122108 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta ceramic-on-ceramic THA with 28 mm articulation
Number of subjects: 345
Study 26122108 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta ceramic-on-ceramic THA with 36 mm articulation
Number of subjects: 345
Study 26122108 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta ceramic-on-ceramic THA (both groups)
Number of subjects: 345
Study 24292904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile learning device (Samsung NC10 Netbook) with interactive exercises
Number of subjects: 55
Study 24292904 — intervention group
Group type: COMPARATOR
Intervention: Traditional library exercise
Number of subjects: 55
Study 21673045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral periodic presumptive treatment (PPT)
Number of subjects: 0
Study 21673045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19843683 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0
Study 19843683 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 16707869 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary pellicle formed on enamel pretreated with unstimulated human saliva for 1 hour or more
Number of subjects: 0
Study 16707869 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary pellicle formed on dentine pretreated with unstimulated human saliva for 2 minutes
Number of subjects: 0
Study 16707869 — intervention group
Group type: COMPARATOR
Intervention: Control group exposed to water for the same times as the intervention
Number of subjects: 0
Study 14713918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg daily and zafirlukast 20 mg twice a day
Number of subjects: 0
Study 14713918 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg daily and placebo
Number of subjects: 0
Study 11158471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 273
Study 11158471 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 273
Study 9209776 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 5 mg
Number of subjects: 32
Study 9209776 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 10 mg
Number of subjects: 32
Study 9209776 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 20 mg
Number of subjects: 32
Study 9209776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9209776 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 20 mg (multiple doses)
Number of subjects: 32
Study 9209776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (overall)
Number of subjects: 32
Study 7802852 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (50 mg, three times a day)
Number of subjects: 122
Study 7802852 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (0.5 mg, three times a day)
Number of subjects: 122
Study 7802852 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem
Number of subjects: 122
Study 2439808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 20
Study 2439808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29861725 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and < 7.0 mmol/L postprandial)
Number of subjects: 41
Study 29861725 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM2 (less tight glycaemic targets, fasting blood glucose < 5.3 mmol/L and < 7.8 mmol/L postprandial)
Number of subjects: 41
Study 29861725 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal glucose tolerance)
Number of subjects: 41
Study 29861725 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM2
Number of subjects: 41
Study 27475042 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 300
Study 27475042 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 300
Study 27475042 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 300
Study 24390775 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (transfusion when hemoglobin fell below 7 g/dL)
Number of subjects: 921
Study 24390775 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (transfusion when hemoglobin fell below 9 g/dL)
Number of subjects: 921
Study 24390775 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 921
Study 24390775 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 921
Study 22506884 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to classical music through computer speakers during injection)
Number of subjects: 73
Study 22506884 — intervention group
Group type: COMPARATOR
Intervention: Control (no music during injection)
Number of subjects: 73
Study 22506884 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 73
Study 22506884 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 73
Study 22506884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 15987865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements (vitamins, minerals, and nutraceuticals)
Number of subjects: 1776
Study 15987865 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplement users
Number of subjects: 1776
Study 15987865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements
Number of subjects: 1776
Study 12099389 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (Genotropin) at a dose of 0.2 IU/kg/day for 2 years (Group 1)
Number of subjects: 26
Study 12099389 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) treatment for one year after the initial trial (Group 2)
Number of subjects: 26
Study 12099389 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2) without treatment
Number of subjects: 26
Study 12099389 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after discontinuation of GH therapy
Number of subjects: 26
Study 12099389 — intervention group
Group type: COMPARATOR
Intervention: Comparison of recent heights between GH-treated group and control group at final examination
Number of subjects: 26
Study 10541761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 30
Study 10541761 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day)
Number of subjects: 30
Study 7546498 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg isradipine SRO at 08:00
Number of subjects: 16
Study 7546498 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg isradipine SRO at 20:00
Number of subjects: 16
Study 7546498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2182350 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily-wear hard (DWH) PMMA contact lens
Number of subjects: 110
Study 2182350 — intervention group
Group type: COMPARATOR
Intervention: Extended-wear (XW) lenses
Number of subjects: 110
Study 43950 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 or 100 mg betadrenol
Number of subjects: 60
Study 43950 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine derivative
Number of subjects: 60
Study 43950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28195973 — intervention group
Group type: EXPERIMENTAL
Intervention: P24 (24 hours recovery)
Number of subjects: 16
Study 28195973 — intervention group
Group type: EXPERIMENTAL
Intervention: P48 (48 hours recovery)
Number of subjects: 16
Study 28195973 — intervention group
Group type: EXPERIMENTAL
Intervention: P72 (72 hours recovery)
Number of subjects: 16
Study 28618005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanabecestat 15 mg
Number of subjects: 40
Study 28618005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanabecestat 50 mg
Number of subjects: 40
Study 28618005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanabecestat (various doses)
Number of subjects: 40
Study 28618005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Number of subjects: 40
Study 25243731 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 32
Study 25243731 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 32
Study 25243731 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 32
Study 23534542 — intervention group
Group type: EXPERIMENTAL
Intervention: Miravirsen 3 mg/kg
Number of subjects: 36
Study 23534542 — intervention group
Group type: EXPERIMENTAL
Intervention: Miravirsen 5 mg/kg
Number of subjects: 36
Study 23534542 — intervention group
Group type: EXPERIMENTAL
Intervention: Miravirsen 7 mg/kg
Number of subjects: 36
Study 23534542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21393207 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 20
Study 21393207 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg once daily
Number of subjects: 20
Study 21393207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe glucuronide
Number of subjects: 20
Study 18640172 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically heated cigarette smoking system (EHCSS, Series K)
Number of subjects: 100
Study 18640172 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarette (CC)
Number of subjects: 100
Study 18640172 — intervention group
Group type: COMPARATOR
Intervention: No-smoking
Number of subjects: 100
Study 16519546 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended adjuvant letrozole (2.5 mg/day)
Number of subjects: 5187
Study 16519546 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 5187
Study 12652495 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment
Number of subjects: 300
Study 12652495 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive abciximab
Number of subjects: 300
Study 12652495 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study 12652495 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of 109 patients with single-vessel stenting of type A/B1 lesions
Number of subjects: 300
Study 11147612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual screen group (sputum cytology + chest X-rays)
Number of subjects: 10040
Study 11147612 — intervention group
Group type: COMPARATOR
Intervention: X-ray only group (annual chest X-rays)
Number of subjects: 10040
Study 9384206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 1015
Study 9384206 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1015
Study 9384206 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FFQ
Number of subjects: 1015
Study 1526558 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% glucose polymer (GP) electrolyte beverage
Number of subjects: 48
Study 1526558 — intervention group
Group type: COMPARATOR
Intervention: Tap water (TW)
Number of subjects: 48
Study 4001757 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-6 containing adenosine triphosphate (three concentrations)
Number of subjects: 16
Study 4001757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 4001757 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-6 containing adenosine triphosphate (average of both sides)
Number of subjects: 16
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (>/=140 mmHg)
Number of subjects: 16485
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: High diastolic blood pressure (>/=90 mmHg)
Number of subjects: 16485
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low systolic blood pressure (<120 mmHg)
Number of subjects: 16485
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low diastolic blood pressure (<80 mmHg)
Number of subjects: 16485
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher heart rates (>/=80 per minute)
Number of subjects: 16485
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pulse pressures (>/=80 mmHg)
Number of subjects: 16485
Study 30101300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16485
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting beta agonist
Number of subjects: 16485
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid
Number of subjects: 16485
Study 30101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of long-acting beta agonist and inhaled corticosteroid
Number of subjects: 16485
Study 26577795 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg
Number of subjects: 309
Study 26577795 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Number of subjects: 309
Study 26577795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 26577795 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 309
Study 24837064 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction (VRD)
Number of subjects: 0
Study 24837064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic Analgesia (HA)
Number of subjects: 0
Study 24837064 — intervention group
Group type: EXPERIMENTAL
Intervention: HA + VRD
Number of subjects: 0
Study 24837064 — intervention group
Group type: COMPARATOR
Intervention: No Treatment Control
Number of subjects: 0
Study 23170866 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodramatic group
Number of subjects: 77
Study 23170866 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic group
Number of subjects: 77
Study 23170866 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 20646599 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV in spine position (PSV-SP)
Number of subjects: 15
Study 20646599 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV in prone position (PSV-PP)
Number of subjects: 15
Study 20646599 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA in spine position (NAVA-SP)
Number of subjects: 15
Study 20646599 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA in prone position (NAVA-PP)
Number of subjects: 15
Study 20646599 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA-PP
Number of subjects: 15
Study 20646599 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA (both positions)
Number of subjects: 15
Study 20646599 — intervention group
Group type: COMPARATOR
Intervention: PRVC-base
Number of subjects: 15
Study 18700689 — intervention group
Group type: EXPERIMENTAL
Intervention: omega 3 fatty acid enhanced supplement with a high ratio of omega3/omega6
Number of subjects: 65
Study 18700689 — intervention group
Group type: EXPERIMENTAL
Intervention: omega 3 fatty acid enhanced supplement with a low ratio of omega3/omega6
Number of subjects: 65
Study 15971400 — intervention group
Group type: EXPERIMENTAL
Intervention: 9HR regimen
Number of subjects: 137
Study 15971400 — intervention group
Group type: COMPARATOR
Intervention: 2HRZ3/4RH2 regimen
Number of subjects: 137
Study 15971400 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy
Number of subjects: 137
Study 12418497 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg SAMe
Number of subjects: 20
Study 12418497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10479180 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-PRP-T-HB
Number of subjects: 0
Study 8804805 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg RU486
Number of subjects: 39
Study 8804805 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg RU486
Number of subjects: 39
Study 8804805 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg RU486
Number of subjects: 39
Study 2010562 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg)
Number of subjects: 0
Study 2010562 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (15 mg)
Number of subjects: 0
Study 6926651 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with infant during the first hour after birth
Number of subjects: 20
Study 31804580 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 47
Study 31804580 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 47
Study 27743941 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa (100mg) and carbidopa (25mg)
Number of subjects: 40
Study 27743941 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 26047420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition fiber tractography and diffusion connectometry analysis
Number of subjects: 3
Study 26047420 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion connectometry analysis
Number of subjects: 3
Study 23636794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (n=50)
Number of subjects: 100
Study 23636794 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy (Control group, n=50)
Number of subjects: 100
Study 22072548 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF/DXM (lenograstim 6 μg/kg plus 8‐mg DXM)
Number of subjects: 26
Study 22072548 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF/placebo
Number of subjects: 26
Study 22072548 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF/DXM
Number of subjects: 26
Study 19304422 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 939
Study 19304422 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative women
Number of subjects: 939
Study 16969894 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral treatment
Number of subjects: 0
Study 16969894 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-out model
Number of subjects: 0
Study 16969894 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian framework with Markov chain Monte Carlo methods
Number of subjects: 0
Study 15512813 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b, three times a week for 1 year
Number of subjects: 384
Study 15512813 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 384
Study 11232001 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (continuous cycle ergometry at approximately 80% of predetermined maximal oxygen uptake for 20 min)
Number of subjects: 17
Study 7851520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unilateral vestibular deafferentation
Number of subjects: 0
Study 7851520 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 2768569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid membrane treatment
Number of subjects: 7
Study 2768569 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment specified)
Number of subjects: 7
Study 5411446 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 13
Study 5411446 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 13
Study 31622421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifty cup
Number of subjects: 237
Study 29733403 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplementation (60 mg iron and 2.8 mg folic acid)
Number of subjects: 1959
Study 29733403 — intervention group
Group type: COMPARATOR
Intervention: 2.8 mg folic acid (Control)
Number of subjects: 1959
Study 27684871 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) with 0.2% ropivacaine (40 mL)
Number of subjects: 22
Study 27684871 — intervention group
Group type: COMPARATOR
Intervention: Non-FICB (control group)
Number of subjects: 22
Study 27684871 — intervention group
Group type: EXPERIMENTAL
Intervention: FICB
Number of subjects: 22
Study 27684871 — intervention group
Group type: COMPARATOR
Intervention: Non-FICB
Number of subjects: 22
Study 25367207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective β‐blocker propranolol (30 μg/kg)
Number of subjects: 43
Study 25367207 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective β1‐blocker metoprolol (40 μg/kg)
Number of subjects: 43
Study 25367207 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐blocker phentolamine (3 mg) after PCI
Number of subjects: 43
Study 21963235 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 55
Study 21963235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 20974318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 150 mg/d
Number of subjects: 90
Study 20974318 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 18515694 — intervention group
Group type: COMPARATOR
Intervention: Continuation/maintenance nortriptyline
Number of subjects: 33
Study 18515694 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuation/maintenance ECT plus nortriptyline
Number of subjects: 33
Study 15782623 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b at 6MIUs.c./three-times-weekly (group A)
Number of subjects: 78
Study 15782623 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b at 3MIUs.c./daily (group B)
Number of subjects: 78